# Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation

Study · id `cardio:ct-nct04864145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04864145](<https://clinicaltrials.gov/study/NCT04864145>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04864145

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

## Technical summary

Registry record NCT04864145. Randomized; single masking; primary purpose treatment. Start 2021-05-21 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT04864145, source copy `cardio:ctgov-nct04864145-2026-04-08`, retrieved 2026-11-18)
- Started: 2021-05-21 (actual) (ClinicalTrials.gov record NCT04864145, source copy `cardio:ctgov-nct04864145-2026-04-08`, retrieved 2026-11-18)
- Primary completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT04864145, source copy `cardio:ctgov-nct04864145-2026-04-08`, retrieved 2026-11-18)
- Completion: 2031-05-30 (anticipated) (ClinicalTrials.gov record NCT04864145, source copy `cardio:ctgov-nct04864145-2026-04-08`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT04864145, source copy `cardio:ctgov-nct04864145-2026-04-08`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04864145-2026-04-08`, retrieved 2026-11-18)

## The registry's words

- Brief title: Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation
- Acronym: SEASON-AR
- Condition: Aortic Valve Disease
- Intervention (Device): Transcatheter Aortic Valve Implantation
- Intervention (Drug): Medical therapy
- Lead sponsor: Nanjing First Hospital, Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Nanjing First Hospital, Nanjing Medical University (`cardio:org-nanjing-first-hospital-nanjing-medical-university`)

## Provenance

Content hash: 0a46b00c66e969bd3c2abcdab4d90f76fa41621954a5e44c76f6519ba51f29d5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
